Posted by Michael Wonder on 15 Mar 2021
ICER to assess treatments for myasthenia gravis
15 March 2021 - Report will be subject of New England CEPAC meeting in September 2021; draft scoping document open to public comment until 2 April 2021
The Institute for Clinical and Economic Reviewannounced today that it will assess the comparative clinical effectiveness and value of efgartigimod (argenx, Halozyme Therapeutics, and Zai Lab) and eculizumab (Soliris, Alexion Pharmaceuticals) for the treatment of myasthenia gravis.
